4/27/2012

A federal appeals court upheld a ruling that a deal between Solvay SA and three other companies to delay generic versions of Solvay's Androgel until 2015 did not violate antitrust laws, as the Federal Trade Commission alleged.

Full Story:
Bloomberg

Related Summaries